Rivaroxaban is the first oral, direct Factor Xa inhibitor to receive approval from regulatory authorities for stroke prevention in patients with AF, based mainly on the Phase III results of the ROCKET AF trial [20]. This evidence concerns the gene F10 and stroke disorder.